Semaglutide vs Tirzepatide: A Side-by-Side Comparison

Semaglutide and tirzepatide are the two most-discussed metabolic peptide therapeutics in current research and clinical literature. They share design elements but differ on the receptor question — and that difference shows up in the trial data.

What they share

Both compounds are long-acting, weekly-administered, fatty-acid-conjugated peptide therapeutics. Both came out of the same broader peptide-engineering program at Novo Nordisk / Eli Lilly. Both have albumin-binding strategies for extended half-life. Both produce clinically meaningful effects on glycemic control and body weight.

Where they differ

Receptor profile:

	Semaglutide	Tirzepatide
GLP-1 receptor	High affinity (native-like)	Moderate affinity (~5x lower than native GLP-1)
GIP receptor	None	High affinity (native-like)
Class	Single-receptor agonist	Dual-receptor agonist

Structural design:

	Semaglutide	Tirzepatide
Length	31 amino acids	39 amino acids
Backbone parent	Human GLP-1	Human GIP (closer to GIP than GLP-1)
Fatty acid chain	C18 (stearic acid)	C20 (eicosanoic acid)
Linker	γ-Glu	γ-Glu

Clinical-trial outcomes (research-context summary):

	Semaglutide 2.4 mg	Tirzepatide 15 mg
HbA1c reduction (T2D trials)	~1.6-1.8%	~2.1-2.3%
Weight reduction (obesity trials)	~15% body weight	~20-22% body weight

The tirzepatide data is consistently larger in magnitude on weight endpoints. The receptor-pharmacology hypothesis — adding GIP receptor activity extends the metabolic ceiling — appears broadly supported.

Tolerability

Both produce gastrointestinal side effects (nausea, occasional vomiting) at therapeutic doses. The published tolerability profiles are broadly comparable, though tirzepatide’s biased GLP-1 receptor pharmacology may reduce some adverse-event categories at equipotent metabolic doses.

Research context implications

If a research program is studying:

• Pure GLP-1 receptor pharmacology → semaglutide is the cleaner reference compound (single receptor)
• Dual incretin pharmacology → tirzepatide is the canonical reference
• Triple agonist comparisons (retatrutide, etc.) → tirzepatide as the dual reference, then triple agonists add a glucagon-receptor dimension

Sourcing notes

Both peptides are widely available as reference standards. Look for HPLC purity >99% for clinical comparison work. Counter-ion identity matters more for these than smaller peptides — acetate is preferred for downstream assays where TFA interferes.

Reference-grade lots should ship with mass-spec confirmation that includes the fatty-acid-conjugated mass (both compounds have characteristic masses around 4.0-4.8 kDa with the fatty-acid linker).